Clinical Trials Directory

Trials / Completed

CompletedNCT00042172

Treatment for Early Memory Loss

Cognitive Enhancers Explored With PET Imaging

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
40 (planned)
Sponsor
University of Iowa · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the effectiveness of donepezil (Aricept) for the treatment of mild cognitive impairment (MCI) in elderly adults. This study will also determine whether adding ginkgo biloba extract (GBE) enhances the effects of donepezil.

Detailed description

Cognition involves important thinking processes such as perception, learning, and reasoning. There are currently no definitive treatments for cognitive deterioration. This study focuses on elderly individuals with MCI because people at a pre-dementia stage may sustain the greatest and most lasting benefit from cognitive-enhancing agents. Patients receive either donepezil or placebo for the first 6 months of the study. In the second 6 months of the study, patients are randomized to receive either donepezil plus GBE or donepezil alone. Positron Emission Tomography (PET), which provides a color-coded image of the brain's blood flow in a particular area, is used to assess brain activity during memory tasks. A PET scan is performed at study entry, 6 months, and 1 year. A vasodilator (a drug that dilates the blood vessels) is administered during the PET imaging procedure to determine whether vascular disease affects memory function. A magnetic resonance imaging (MRI) scan is also taken to view the brain.

Conditions

Interventions

TypeNameDescription
DRUGDonepezil
DRUGGinkgo Biloba Extract

Timeline

Start date
2002-06-01
Primary completion
2004-09-01
Completion
2004-09-01
First posted
2002-07-26
Last updated
2014-03-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00042172. Inclusion in this directory is not an endorsement.